Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$----
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
Debt to Equity
--
ROE
--
ROCE
--
Div. Yield
--
Book Value
--
EPS
--
CFO
$-11.86 Mln
EBITDA
$-17.47 Mln
Net Profit
$-30.88 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Nutriband Inc. Warrant (NTRBW)
| -4.64 | -39.04 | 14.10 | 270.83 | -44.94 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
|
|---|---|---|
|
Nutriband Inc. Warrant (NTRBW)
| 284.61 | -88.54 |
|
S&P Small-Cap 600
| 7.01 | 13.89 |
|
BSE Sensex
| 8.10 | 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release... transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida. Address: 121 South Orange Avenue, Orlando, FL, United States, 32801 Read more
Founder, President, Company Secretary & Executive Chairman of the Board
Mr. Serguei Melnik
Founder, President, Company Secretary & Executive Chairman of the Board
Mr. Serguei Melnik
Headquarters
Orlando, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Nutriband Inc Warrant (NTRBW) is $1.34 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Nutriband Inc Warrant (NTRBW) has given a return of -44.94% in the last 3 years.
Nutriband Inc Warrant (NTRBW) has a market capitalisation of -- as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Nutriband Inc Warrant (NTRBW) and enter the required number of quantities and click on buy to purchase the shares of Nutriband Inc Warrant (NTRBW).
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida. Address: 121 South Orange Avenue, Orlando, FL, United States, 32801
The CEO & director of Mr. Serguei Melnik. is Nutriband Inc Warrant (NTRBW), and CFO & Sr. VP is Mr. Serguei Melnik.
There is no promoter pledging in Nutriband Inc Warrant (NTRBW).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Nutriband Inc. Warrant (NTRBW) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Nutriband Inc Warrant (NTRBW) was $0 Mln.
$0.06
(
